Skip to main
AMGN

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 18 analyst ratings
Hold
Strong Buy 11%
Buy 17%
Hold 67%
Sell 6%
Strong Sell 0%

Bulls say

Amgen is expected to post strong results in the first quarter of 2026, with product sales and operating margin being the lowest of the year due to inventory build and generic competition, but emerging therapies such as MariTide and olpasiran may provide upside. However, the company also faces headwinds from biosimilar/generic competition and potential pricing/regulatory risks, leading to a steady but limited expected revenue growth range of $36-$38 billion until 2030. Upside risks include strong performance from growth products and positive pipeline data, while downside risks include product and regulatory risks and increased concerns in the biopharma industry.

Bears say

Amgen is facing upcoming patent expiries for its key franchises and its limited pipeline visibility may require continued business development for sustained topline growth. On the other hand, their current products and pipeline show high clinical potential and with the assumption of consistent data and targeted readout in 4Q26, they may reach total revenues of $42.0B+ by 2030. However, the limited window into their next major growth drivers leaves the stock fairly valued and warrants a Hold rating with a price target of $318.

Amgen (AMGN) has been analyzed by 18 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 17% recommend Buy, 67% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 18 analysts, Amgen (AMGN) has a Hold consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $352.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $352.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.